Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis
Yu-Tuan Wu,1,* Zhou Xu,1,* Ke Zhang,2,* Jiu-song Wu,3,* Xin Li,1,* Bilal Arshad,1 Ying-Cun Li,3 Zhong-Liang Wang,2 Hong-Yuan Li,1 Kai-Nan Wu,1 Ling-Quan Kong1 1Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China; 2Departm...
Saved in:
Main Authors: | Wu Y (Author), Xu Z (Author), Zhang K (Author), Wu J (Author), Li X (Author), Arshad B (Author), Li Y (Author), Wang Z (Author), Li H (Author), Wu K (Author), Kong L (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2018-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lapatinib, trastuzumab or the combination added to neoadjuvant chemotherapy for breast cancer
by: Quan Liang, et al.
Published: (2016) -
Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
by: Li S, et al.
Published: (2018) -
Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022) -
The Correlation of Fibronectin and Vimentin Expression on Anthracycline-Based Neoadjuvant Chemotherapy Response in Stage IIIA and Luminal Subtype IIIB Breast Cancer
by: Feri Nugroho, et al.
Published: (2022) -
The Hippo Transducer YAP/TAZ as a Biomarker of Therapeutic Response and Prognosis in Trastuzumab-Based Neoadjuvant Therapy Treated HER2-Positive Breast Cancer Patients
by: Jia-qi Yuan, et al.
Published: (2020)